Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113568 · ClinicalTrials.gov registry record · Phase 3
Safety Study of XP12B in Women With Menorrhagia
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 784
- Enrollment target
NCT00113568: Completed Phase 3 study, sponsored by Ferring Pharmaceuticals.
NCT00113568 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 784 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00113568, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 784 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.
Primary Outcome
An adverse event is any untoward, undesired, unplanned clinical event in the form of signs. symptoms, disease, or laboratory or physiological observations occurring in a human being participating in a clinical study with a sponsor study drug, regardless of causal relationship.
Interventions
- DRUG Tranexamic acid tablets (XP12B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 784 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
What the finished NCT00113568 record still lists
NCT00113568 is an interventional study that assigns participants to a tested intervention. The registered 784 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Tranexamic acid tablets (XP12B) is the first listed.
NCT00113568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00113568 about?
NCT00113568 is a clinical study titled "Safety Study of XP12B in Women With Menorrhagia". The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.
What is the current status of trial NCT00113568?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 784 participants. The study started on 2005-06. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00113568?
The interventions under investigation include: Tranexamic acid tablets (XP12B) (DRUG).
Who is sponsoring clinical trial NCT00113568?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00113568's enrollment target sits among peer trials
784 433rd of 2000 higher than 1,568 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06118723 · 784 participants
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- NCT06498128 · 785 participants
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
- NCT06575192 · 783 participants · Phase 3
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
- NCT07276724 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia